Compare AbCellera Biologics Inc (ABCL) vs Walmart Stores Inc (WMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Walmart Stores Inc — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Walmart Stores Inc trades at $113.05 (market cap $887.64B). The key difference: Walmart Stores Inc is far larger — about 377.7× AbCellera Biologics Inc's market cap, and Walmart Stores Inc pays a 0.89% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WMT | |
|---|---|---|
Market Cap | $2.35B | $887.64B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $134.20 |
52-Week Low | $2.78 | $94.40 |
Enterprise Value | $1.99B | $951.09B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Walmart's stock trades at $110.65, down 1.06% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $681.0B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent news highlights Walmart's AI initiatives and expansion of drone deliveries, while analyst consensus remains strongly bullish with a $141.64 price target.
The outlook is positive given Walmart's consistent earnings beats and strategic investments in technology, though near-term price pressure and competitive threats from Amazon pose risks. The stock offers a compelling entry point for long-term investors seeking defensive exposure with growth potential, supported by solid fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
